Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004077790 | SCV003544928 | uncertain significance | not specified | 2024-09-08 | criteria provided, single submitter | clinical testing | The c.63G>C (p.E21D) alteration is located in exon 5 (coding exon 1) of the GPRASP2 gene. This alteration results from a G to C substitution at nucleotide position 63, causing the glutamic acid (E) at amino acid position 21 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003936637 | SCV004751979 | benign | GPRASP2-related disorder | 2021-06-16 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |